Once-weekly teriparatide reduces the risk of vertebral fracture in patients with various fracture risks: subgroup analysis of the Teriparatide Once-Weekly Efficacy Research (TOWER) trial

Once-weekly teriparatide reduces the risk of vertebral fracture in patients with various fracture risks: subgroup analysis of the Teriparatide Once-Weekly Efficacy Research (TOWER) trial

Once-weekly teriparatide (human parathyroid hormone [1–34]) (56.5 μg for 72 weeks) injections provided a vertebral fracture risk reduction in Japanese osteoporotic patients evaluated in the Teriparatide Once-Weekly Efficacy Research (TOWER) trial. Using data from the TOWER trial, a subgroup analysis...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of bone and mineral metabolism 2014-07, Vol.32 (4), p.441-446
Hauptverfasser: Nakano, Tetsuo, Shiraki, Masataka, Sugimoto, Toshitsugu, Kishimoto, Hideaki, Ito, Masako, Fukunaga, Masao, Hagino, Hiroshi, Sone, Teruki, Kuroda, Tatsuhiko, Nakamura, Toshitaka
Format: Artikel
Sprache:eng
Schlagworte:
Aged
Aged, 80 and over
Animals
Bone Density - drug effects
Female
Fractures, Bone - drug therapy
Humans
Male
Medicine
Medicine & Public Health
Metabolic Diseases
Original Article
Orthopedics
Osteoporosis - drug therapy
Spinal Fractures - drug therapy
Teriparatide - therapeutic use
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Once-weekly teriparatide (human parathyroid hormone [1–34]) (56.5 μg for 72 weeks) injections provided a vertebral fracture risk reduction in Japanese osteoporotic patients evaluated in the Teriparatide Once-Weekly Efficacy Research (TOWER) trial. Using data from the TOWER trial, a subgroup analysis was performed to study the efficacy of once-weekly teriparatide for a variety of baseline clinical risk factors in placebo ( n  = 281) and teriparatide ( n  = 261) groups. Significant fracture risk reductions were observed in the subgroups of individuals aged
ISSN:0914-8779
1435-5604
DOI:10.1007/s00774-013-0505-2